Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $128.00 short put and a strike $123.00 long put offers a potential 13.9% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $128.00 by expiration. The full premium credit of $0.61 would be kept by the premium seller. The risk of $4.39 would be incurred if the stock dropped below the $123.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Eli Lilly to offer half-price version of insulin amid Trump’s pressure to lower drug prices
Tue, 05 Mar 2019 23:29:17 +0000
FOX News medical correspondent Dr. Marc Siegel discusses how Eli Lilly announced plans to lower the cost of insulin amid President Trump’s push to lower drug prices.
Lilly to Bring Half-Priced Version of Popular Humalog Insulin
Tue, 05 Mar 2019 14:00:02 +0000
Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.
Eli Lilly will offer a half-off version of its popular insulin drug Humalog
Tue, 05 Mar 2019 12:11:00 +0000
Amid increasing pressure on the pharmaceutical industry to lower prices, drugmaker Eli Lilly is planning to sell a cheaper version of Humalog, its popular insulin product.
Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults
Tue, 05 Mar 2019 11:45:00 +0000
INDIANAPOLIS, March 5, 2019 /PRNewswire/ — Eli Lilly and Company (LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality® (galcanezumab-gnlm) injection for the preventive treatment of episodic cluster headache in adults. The sBLA is based on data from a Phase 3 study that evaluated the safety and efficacy of Emgality (galcanezumab-gnlm) injection 300mg in 106 adult patients with episodic cluster headache. Emgality was previously granted Breakthrough Therapy Designation by the FDA in September 2018 for the preventive treatment of episodic cluster headache, indicating the significant unmet need for this debilitating condition for which there are currently no approved preventive medications.
Drugmaker Eli Lilly cutting price of popular insulin Humalog
Tue, 05 Mar 2019 01:54:48 +0000
Eli Lilly said it plans to roll out a half-price version of its Humalog insulin, an effort that comes amid rising scrutiny and criticism over the surging cost of the life-saving medication.
Also on Market Tamer…
Follow Us on Facebook